Rein Therapeutics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 3

Employees

  • Stock Symbol
  • RNTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.44
  • (As of Friday Closing)

Rein Therapeutics General Information

Description

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.

Contact Information

Website
www.reintx.com
Formerly Known As
Renegade Therapeutics, Aileron Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12407 North Mopac Expressway
  • Suite 250 Number 390
  • Austin, TX 78758
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 12407 North Mopac Expressway
  • Suite 250 Number 390
  • Austin, TX 78758
  • United States

Rein Therapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rein Therapeutics Stock Performance

As of 14-Feb-2025, Rein Therapeutics’s stock price is $2.44. Its current market cap is $52.9M with 21.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.44 $2.35 $1.61 - $7.42 $52.9M 21.7M 102K -$2.88

Rein Therapeutics Financials Summary

As of 30-Sep-2024, Rein Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 99,785 2,826 (14,647) (1,056)
Revenue 0 0 0 0
EBITDA (29,070) (15,957) (27,160) (26,043)
Net Income (29,241) (15,732) (27,329) (26,164)
Total Assets 104,217 106,008 22,007 48,481
Total Debt 0 48 33 162
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Rein Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in o
Drug Discovery
Austin, TX
3 As of 2024

San Francisco, CA
 

Sugar Land, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rein Therapeutics Competitors (134)

One of Rein Therapeutics’s 134 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Tvardi Therapeutics Venture Capital-Backed Sugar Land, TX
Kite Pharma Formerly VC-backed Santa Monica, CA
NexImmune Formerly VC-backed Gaithersburg, MD
TScan Therapeutics Formerly VC-backed Waltham, MA
You’re viewing 5 of 134 competitors. Get the full list »

Rein Therapeutics Patents

Rein Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020241429-A1 Peptidomimetic macrocycles and uses thereof Inactive 15-Mar-2019
US-20200289609-A1 Peptidomimetic macrocycles and uses thereof Inactive 15-Mar-2019
EP-3938051-A4 Peptidomimetic macrocycles and uses thereof Inactive 15-Mar-2019
EP-3938051-A1 Peptidomimetic macrocycles and uses thereof Inactive 15-Mar-2019
CA-3132993-A1 Peptidomimetic macrocycles and uses thereof Pending 15-Mar-2019 A61K38/12
To view Rein Therapeutics’s complete patent history, request access »

Rein Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rein Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Rein Therapeutics‘s full profile, request access.

Request a free trial

Rein Therapeutics Acquisitions (1)

Rein Therapeutics’s most recent deal was a Merger/Acquisition with Lung Therapeutics. The deal was made on 31-Oct-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Lung Therapeutics 31-Oct-2023 Merger/Acquisition Drug Discovery
To view Rein Therapeutics’s complete acquisitions history, request access »

Rein Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Rein Therapeutics’s complete esg history, request access »

Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Lung Therapeutics Austin, TX 2013

Rein Therapeutics FAQs

  • When was Rein Therapeutics founded?

    Rein Therapeutics was founded in 2001.

  • Where is Rein Therapeutics headquartered?

    Rein Therapeutics is headquartered in Austin, TX.

  • What is the size of Rein Therapeutics?

    Rein Therapeutics has 3 total employees.

  • What industry is Rein Therapeutics in?

    Rein Therapeutics’s primary industry is Drug Discovery.

  • Is Rein Therapeutics a private or public company?

    Rein Therapeutics is a Public company.

  • What is Rein Therapeutics’s stock symbol?

    The ticker symbol for Rein Therapeutics is RNTX.

  • What is the current stock price of Rein Therapeutics?

    As of 14-Feb-2025 the stock price of Rein Therapeutics is $2.44.

  • What is the current market cap of Rein Therapeutics?

    The current market capitalization of Rein Therapeutics is $52.9M.

  • Who are Rein Therapeutics’s competitors?

    Pliant Therapeutics, Tvardi Therapeutics, Kite Pharma, NexImmune, and TScan Therapeutics are some of the 134 competitors of Rein Therapeutics.

  • What is Rein Therapeutics’s annual earnings per share (EPS)?

    Rein Therapeutics’s EPS for 12 months was -$2.88.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »